# US 2026/0224641 A1 · Jellyfish collagen use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0224641 A1
- Document ID: US20260224641A1
- Status: Published application
- Kind: A1
- Application number: 19/637,493
- Filed: 2026-04-02
- Published: 2026-08-06
- Earliest claimed: 2020-04-07
- Assignees: Jellagen Limited
- Applicants: Jellagen Limited
- Inventors: Andrew Mearns SPRAGG
- Web page: https://patentgrep.com/patent/US20260224641A1

## CPC

- A61K 35/614: Cnidaria, e.g. sea anemones, corals, coral animals or jellyfish
- A61L 26/0033: {Collagen}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 15/325: {Collagen}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of jellyfish collagen in the treatment of wounds and the manufacture of said jellyfish collagen.

## Claims

### Claim 1

A method for the treatment of a wound, the method comprising administration of a composition comprising jellyfish collagen to a subject in need thereof, wherein the jellyfish collagen is in the form of a micronised powder.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the wound is:
not associated with Epidermolysis Bullosa, or
wherein the jellyfish collagen is not in a hydrolysate form, or
wherein the jellyfish collagen is in its atelo form, or
wherein the jellyfish collagen is in its telo form, or
wherein the jellyfish collagen is thiolated, or
wherein the source of the jellyfish collagen is from the sub-phylum Scyphozoa.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the source of the jellyfish collagen is selected from the group consisting of: Rhizostomas pulmo, Rhopilema esculentum, Rhopilema nomadica, Stomolophus meleagris, Aurelia sp., Cassiopea andromeda, Nemopilema nomurai, or any combination thereof.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the jellyfish collagen is cross-linked.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the jellyfish collagen is non-cross-linked.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the composition further comprises at least one growth factor or at least one antimicrobial compound.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the at least one growth factor is Platelet Rich Plasma (PRP), Epithelial Growth Factor 38 (EGF), Transforming Growth Factor-Beta (TGF-B, TGF-B2, TGF-B3), Hepatocyte Growth Factor (HGF), Keratinocyte Growth Factor (KGF), Granulocyte-Monocyte Colony Stimulating Growth Factor, Platelet Derived Growth Factor, Insulin-like Growth Factor 1 (IGF1), basic Fibroblast Growth Factor (bFGF), and/or Vascular 5 Endothelial Growth Factor (VEGF), or any combination thereof.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the at least one antimicrobial compound is nano silver, penicillin, ofloxacin, tetracycline, aminoglycosides, erythromycin, gentamycin, flucloxacillin, clarithromycin, doxycycline, gentamicin, metronidazole, co-amoxiclav, co-trimoxazole (in penicillin), ceftriaxone, piperacillin with tazobactam, clindamycin, ciprofloxacin, vancomycin, teicoplanin, linezolid, and/or the standard of care antimicrobial agent, or any combination thereof.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said collagen is administered at a dose from 0.01 g/L to 200 g/L, preferably 1 g/L to 50 g/L, per administration.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the jellyfish collagen further comprises a pharmaceutically acceptable excipient and/or carrier, and/or a pharmaceutically active ingredient.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the pharmaceutically active ingredient is lidocaine, preferably at a concentration of 0.1 to 2%.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the wound to be treated is a pressure sore, a transplant site, a surgical wound, an ulcer, preferably a diabetic ulcer, a thermal burn, a chemical burn, an electrical burn, a laceration, an abrasion, a puncture, an avulsion, a seroma, and/or a hematoma.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the micronised powder has a particle size of 1 μm to 1000 μm, preferably wherein the micronised powder has a particle size of 200 μm to 500 μm.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the composition promotes improved angiogenesis in a treated wound, preferably wherein the improved angiogenesis is relative to an untreated wound and/or a wound treated with bovine collagen.
